The objective of this study is to evaluate the complete response rate after a short induction treatment with rituximab (375mg/m2)and bendamustine (90mg/m2)in In Elderly (≥ 60 years old) patients with untreated Follicular lymphoma, with an intermediate or high FLIPI score and without high tumor burden.

This short induction is followed by a rituximab (375mg/m2)maintenance/ Induction schedule:Rituximab+Bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, rituximab on day 22, Bendamustine on Day 29, Bendamustine on Day 30 Maintenance schedule: 12 infusions of rituximab, each 8 weeks

BRIEF: Bendamustine and Rituximab In Elderly Follicular: A Multicentric Phase II Study Evaluating the Benefit of a Short Induction Treatment by Bendamustine and Rituximab Followed by Maintenance Therapy With Rituximab In Elderly (≥ 60 Years Old) Patients With Untreated Follicular Lymphoma Patients, With an Intermediate or High FLIPI Score

Partial and objective response rates at the end of induction phase [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Duration of response [ Time Frame: From the time of attainment of CR or PR to the date of first documented disease progression, relapse or death from any cause ] [ Designated as safety issue: No ]

Progression free survival [ Time Frame: From the date of randomization to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause. ] [ Designated as safety issue: No ]

Overall survival [ Time Frame: From the date of randomization to the date of death from any cause ] [ Designated as safety issue: No ]

Time before retreatment [ Time Frame: From the end of primary treatment until the institution of the next therapy ] [ Designated as safety issue: No ]

Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01313611